CRC Research Update — November 01, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Sunday, November 01, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TRIAL DATA
Final overall survival analysis of CheckMate-8HW supports nivolumab plus ipilimumab in first-line MSI-H/dMMR metastatic CRCThe phase 3 CheckMate-8HW trial presented final overall survival results at ESMO 2026, evaluating nivolumab plus ipilimumab versus nivolumab monotherapy or chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer. (Targeted Oncology)
-
RESEARCH
Immune exclusion signature predicts shorter survival in high-risk stage II colon cancerIn the phase 3 TOSCA trial, a transcriptional signature characterized by low immune cell infiltration and high TGF-β signaling was observed in 28% of high-risk stage II patients and associated with shorter disease-free survival (HR=2.22, p=0.036). (Translational Oncology)
-
RESEARCH
Review examines clinical utility of ctDNA for molecular residual disease detection in colorectal cancerWhile ctDNA detection after curative-intent treatment is a strong prognostic biomarker, randomized trials show mixed results: ctDNA-informed management reduced adjuvant chemotherapy in stage II colon cancer but did not establish non-inferiority in stage III, and cytotoxic escalation for ctDNA-positive MRD has not improved recurrence-free survival. (Lancet Regional Health Western Pacific)
-
LIVING WITH CRC
Machine learning model predicts severe neuropathy risk in CRC patients with diabetes receiving oxaliplatinAn XGBoost model achieved an AUC of 0.880 in predicting dose-limiting toxicity among 513 CRC patients with diabetic peripheral neuropathy, identifying cumulative oxaliplatin dose, poor glycemic control (HbA1c > 8.0%), and systemic inflammation as key risk factors. (Journal of Visualized Experiments)
This week's research highlights advances in biomarker-driven treatment, prognostic signatures, and supportive care for patients across disease stages.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data